TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22470117

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) resistance without rifampin resistance
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Multidrug resistance
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: INH-resistant cases during the continuation phase of treatment (after 3 months)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Drug-susceptible cases infected with 'modern' Beijing lineage strains
Number of subjects: 186
Study: 19264840

Group type: EXPERIMENTAL
Intervention: High protein-high red meat (HP) diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: High carbohydrate (HC) diet
Number of subjects: 33
Study: 17135217

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Azathioprine plus methylprednisolone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 52
Study: 15083919

Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 11991558

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 88 microg twice daily
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (Z) 20 mg twice daily
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 11713144

Group type: EXPERIMENTAL
Intervention: Volume-assist control (56% usage)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) or SIMV with pressure support
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pressure-control ventilation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tidal volume (mean +/- SD)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Plateau pressures (Pplats)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 74
Study: 9203448

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8135107

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lioresal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3615688

Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose = 233 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29369537

Group type: EXPERIMENTAL
Intervention: Patiromer 16.8 g/day (divided into two doses) with individualized titration
Number of subjects: 63
Study: 27353358

Group type: EXPERIMENTAL
Intervention: Stent graft
Number of subjects: 293

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 293
Study: 24279685

Group type: EXPERIMENTAL
Intervention: Everolimus with mycophenolate and CNI withdrawal (CNI-WD)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (Cyclosporin, mycophenolate and steroids)
Number of subjects: 126
Study: 24373555

Group type: EXPERIMENTAL
Intervention: Mixed tocotrienols 200 mg twice daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 20360491

Group type: EXPERIMENTAL
Intervention: Single injection subcutaneous digital nerve block (SDNB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional (two injection) digital nerve block (TDNB)
Number of subjects: 76
Study: 18822255

Group type: EXPERIMENTAL
Intervention: Early specific counselling about 'unrestricted motility' during maternity stay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early specific counselling about 'unrestricted motility'
Number of subjects: 0
Study: 16491747

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10), once each week, for 4 times
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Medicine group (Yiqi Jianpi Oral Liquid, twice each day, for 4 weeks)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 222
Study: 12834665

Group type: EXPERIMENTAL
Intervention: Generic timolol products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betimol, Optipranolol, Timoptic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic timolol XE gel-forming solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betagan, Betoptic S, Ocupress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betoptic S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ocupress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilopine gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azopt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trusopt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cosopt (timolol 0.5% plus dorzolamide 2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15% with Purite (Alphagan-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumigan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Travatan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescula
Number of subjects: 0
Study: 10799190

Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin chloride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Simple saline (control group)
Number of subjects: 36
Study: 9008994

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midlaser therapy with TMJ/occlusal stabilization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conservative management alone
Number of subjects: 20
Study: 1503285

Group type: COMPARATOR
Intervention: Bupivacaine alone (Group B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bupivacaine combined with fentanyl (Group B+F)
Number of subjects: 14
Study: 28592888

Group type: EXPERIMENTAL
Intervention: GRAALL treatment
Number of subjects: 127
Study: 29106437

Group type: EXPERIMENTAL
Intervention: 120 units of abobotulinumtoxinA injected in 5 equal aliquots (24 units each) into 5 injection sites in the glabellar complex
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 120 units of abobotulinumtoxinA
Number of subjects: 30
Study: 24359563

Group type: EXPERIMENTAL
Intervention: Web-based intervention (WBI; Avanti)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 22472580

Group type: EXPERIMENTAL
Intervention: Exercise intervention over 12 months
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study: 20553679

Group type: EXPERIMENTAL
Intervention: Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Single GnRH-agonist injection
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Repeated dosing of GnRH-agonist
Number of subjects: 7
Study: 18295023

Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression (infliximab 5 mg/kg at weeks 0, 2, and 6, plus azathioprine)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional management (corticosteroids followed by azathioprine and infliximab)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 133
Study: 16945127

Group type: EXPERIMENTAL
Intervention: Yoga practitioners (combined yoga practices)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-yoga group (control)
Number of subjects: 0
Study: 14636490

Group type: EXPERIMENTAL
Intervention: Automatic analysis of the SomnoStar 4100 system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Manual analysis (considered the gold standard)
Number of subjects: 28
Study: 11087536

Group type: EXPERIMENTAL
Intervention: Apple polyphenols (APP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apple condensed tannins (ACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apple polyphenols (APP) and ACT
Number of subjects: 0
Study: 9339157

Group type: EXPERIMENTAL
Intervention: One-half-inch shoe-lift applied to the contralateral, nonimmobilized shoe
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: One-inch shoe-lift applied to the contralateral, nonimmobilized shoe
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 8

Group type: COMPARATOR
Intervention: Knee immobilized
Number of subjects: 8
Study: 8458247

Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cefotaxime plus metronidazole
Number of subjects: 164
Study: 3513319

Group type: EXPERIMENTAL
Intervention: Prednimustine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 30013325

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Tenecteplase (serious stroke subgroup, NIHSS >12)
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1390
Study: 26671202

Group type: EXPERIMENTAL
Intervention: Automated fractional skin microneedling (0.5 mm depth) followed by application of topical anesthetic cream (Lidocaine 2.5% + Prilocaine 2.5%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topical anesthesia alone
Number of subjects: 15
Study: 24376248

Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound (MSUS) assessment
Number of subjects: 53
Study: 22676346

Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Visual Inspection
Number of subjects: 40
Study: 20346190

Group type: EXPERIMENTAL
Intervention: Fibre-free diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibre-supplemented diet (14 g/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline normal diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibre-supplemented diet
Number of subjects: 0
Study: 18383654

Group type: EXPERIMENTAL
Intervention: Mammographic screening (7 screening mammograms)
Number of subjects: 160000

Group type: COMPARATOR
Intervention: Mammographic screening
Number of subjects: 160000
Study: 15213095

Group type: EXPERIMENTAL
Intervention: ICE consolidation therapy (idarubicin 9 mg/m2 x 3; cytarabine 3 g/m2 twice a day on days 1, 3, 5, 7; etoposide 75 mg/m2 x 7)
Number of subjects: 202

Group type: COMPARATOR
Intervention: IcE consolidation therapy (cytarabine 100 mg/m2 daily x 5, idarubicin x 2, etoposide x 5)
Number of subjects: 202
Study: 12094184

Group type: EXPERIMENTAL
Intervention: Supervised exercise training for 3 months followed by home-based training for 9 months
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study: 10028221

Group type: EXPERIMENTAL
Intervention: Intervention participation
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Assessment attrition
Number of subjects: 667
Study: 7726307

Group type: EXPERIMENTAL
Intervention: Fluvoxamine followed by exposure in vivo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Psychological panic management followed by exposure in vivo
Number of subjects: 96

Group type: COMPARATOR
Intervention: Exposure in vivo alone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo followed by exposure in vivo
Number of subjects: 96
Study: 1827621

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (0.6 mg/kg total body weight)
Number of subjects: 12
Study: 6119098

Group type: EXPERIMENTAL
Intervention: Quazepam 7.5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quazepam 30 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quazepam 45 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Quazepam 0 mg (placebo)
Number of subjects: 15
Study: 31004339

Group type: EXPERIMENTAL
Intervention: Autologous muscle-derived cell (MDC) injection
Number of subjects: 20
Study: 27765876

Group type: EXPERIMENTAL
Intervention: Home gardening participation
Number of subjects: 8500
Study: 26113648

Group type: EXPERIMENTAL
Intervention: 14 g of free essential amino acids (EAA) with high leucine levels
Number of subjects: 24

Group type: COMPARATOR
Intervention: Balanced amino acid mixture containing both EAA and non-EAA as present in whey protein
Number of subjects: 24
Study: 23261050

Group type: EXPERIMENTAL
Intervention: Self-administration of intranasal live attenuated influenza vaccine (SA-LAIV)
Number of subjects: 4561

Group type: COMPARATOR
Intervention: Health care provider administration of intranasal live attenuated influenza vaccine (HCP-LAIV)
Number of subjects: 4561
Study: 21279450

Group type: EXPERIMENTAL
Intervention: Support for in-pharmacy vaccination services
Number of subjects: 437

Group type: COMPARATOR
Intervention: Neighborhood characteristics (high percent of minority residents)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Neighborhood characteristics (high percent of foreign-born residents)
Number of subjects: 437
Study: 18802735

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-irradiation
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (no neoadjuvant therapy)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study: 16452054

Group type: EXPERIMENTAL
Intervention: Acid loading (ammonium chloride)
Number of subjects: 24
Study: 14646682

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison among treatment groups
Number of subjects: 28
Study: 11074193

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at low stimulation (stimulation detection)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at high stimulation (maximum tolerability, maximum 1.75 mA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study: 8985623

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1280910

Group type: EXPERIMENTAL
Intervention: Surgical treatment for lateral epicondylitis
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cadaveric control specimens
Number of subjects: 23
Study: 3926808

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5-0.75 micrograms/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 56
Study: 30151895

Group type: EXPERIMENTAL
Intervention: 0.4 ml of daily olive oil supplementation per rooster (Group 3)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.2 ml of daily olive oil supplementation per rooster (Group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard diet without olive oil supplementation (Group 1)
Number of subjects: 3
Study: 27380342

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 24739333

Group type: EXPERIMENTAL
Intervention: Ghrelin (5.0 μg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 22462549

Group type: EXPERIMENTAL
Intervention: Healthy.me (web-based personally controlled health management system)
Number of subjects: 600

Group type: COMPARATOR
Intervention: 6-month waitlist (control group)
Number of subjects: 600
Study: 20147689

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 188

Group type: COMPARATOR
Intervention: Traditional field outreach
Number of subjects: 188
Study: 17521604

Group type: EXPERIMENTAL
Intervention: Self-Focused Attention (SFA) condition
Number of subjects: 44

Group type: COMPARATOR
Intervention: Task-Focused Attention (TFA) condition
Number of subjects: 44
Study: 16126314

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 16
Study: 12171451

Group type: EXPERIMENTAL
Intervention: Experimental group (nutrition intervention)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 10616997

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg orally per day, started 3 weeks preoperatively)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7488409

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1000 mg daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 500 mg daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cytokeratin assay
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Five tumour marker assays
Number of subjects: 94
Study: 2301519

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 50 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 100 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 200 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 400 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 600 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mifepristone (RU‐486) 0 mg
Number of subjects: 180
Study: 6163362

Group type: EXPERIMENTAL
Intervention: Kinesthetic biofeedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 20
Study: 31365099

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (30 μg/d)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 μg/d)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 913
Study: 28087235

Group type: EXPERIMENTAL
Intervention: Hand ventilation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Machine ventilation
Number of subjects: 36
Study: 25877442

Group type: EXPERIMENTAL
Intervention: 200 mg Lidose hard capsule
Number of subjects: 24

Group type: COMPARATOR
Intervention: 145 mg nanoparticle tablet
Number of subjects: 24
Study: 24408766

Group type: EXPERIMENTAL
Intervention: WBV 2 mm [45 Hz and 2 mm]
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WBV 4 mm [45 Hz and 4 mm]
Number of subjects: 8

Group type: COMPARATOR
Intervention: No WBV
Number of subjects: 8
Study: 22999135

Group type: EXPERIMENTAL
Intervention: Complex nondrug intervention including actively approaching counseling and caregiver support groups
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 390
Study: 19152681

Group type: EXPERIMENTAL
Intervention: Eligibility fraction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Enrolment fraction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Number needed to screen (NNS)
Number of subjects: 148
Study: 17223857

Group type: EXPERIMENTAL
Intervention: Brivaracetam (10-1400 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brivaracetam (1400 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brivaracetam (150 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brivaracetam (600 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brivaracetam (150 mg) with high-fat meal
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 14707412

Group type: EXPERIMENTAL
Intervention: 30 g L-arginine infusion
Number of subjects: 55
Study: 11730275

Group type: EXPERIMENTAL
Intervention: Resting period (R) after a protein meal (1.2 g/kg b.w. of protein)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Behavioural stress period (S) after a protein meal (1.2 g/kg b.w. of protein)
Number of subjects: 13
Study: 9570827

Group type: EXPERIMENTAL
Intervention: Symmetric dialysis method for determining free 1,25(OH)2D
Number of subjects: 23

Group type: COMPARATOR
Intervention: Centrifugal ultrafiltration method for determining free 1,25(OH)2D
Number of subjects: 23
Study: 8053797

Group type: EXPERIMENTAL
Intervention: Rehabilitation program based on eye‐head coupling (RG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 1827271

Group type: EXPERIMENTAL
Intervention: Metoclopramide 4 mg/kg as a single intravenous dose (regimen A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Metoclopramide 3 mg/kg in two doses (regimen B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Regimen A (single dose)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Regimen B (divided dose)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 65
Study: 31390660

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31050359

Group type: EXPERIMENTAL
Intervention: IMPL/DBBM/CM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DBBM/CM
Number of subjects: 30

Group type: COMPARATOR
Intervention: SH
Number of subjects: 30
Study: 28409564

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 26546647

Group type: EXPERIMENTAL
Intervention: Intervention (system change innovation to connect patients to primary care)
Number of subjects: 140
Study: 23523988

Group type: EXPERIMENTAL
Intervention: Paroxetine plus brief alcohol intervention (BI)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Paroxetine alone
Number of subjects: 83
Study: 21084429

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Capecitabine plus docetaxel (CD)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Crossover groups (GD→C or CD→G)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 475
Study: 19247023

Group type: EXPERIMENTAL
Intervention: Surgery (laparoscopic adrenalectomy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 45